Gilead reports Q2 adjusted EPS $1.34, consensus $1.64

Reports Q2 revenue $6.6B, consensu $6.44B. “It was another strong quarter for Gilead, with continued commercial and clinical momentum,” said Daniel O’Day, Gilead’s Chairman and Chief Executive Officer. “11% year-over-year growth across our base business was driven by our diverse portfolio of therapies for HIV, Oncology, and Liver Disease. We received positive regulatory updates for six of our therapies and presented a large body of data on our pipeline, reinforcing our growing potential to help more patients and communities worldwide.”